Trastuzumab improves survival outcomes for patients with HER2-positive (HER2+) breast
cancer, yet not all such women receive this important therapy. Trastuzumab was approved …

Background Economic evaluations of health interventions pose a particular challenge for
reporting because substantial information must be conveyed to allow scrutiny of study …

The advent of targeted anticancer therapies over the past few decades has reinvigorated the
field of cancer therapeutics, with the promise of increased cancer cure rates accompanied …

Background Breast cancer is the second most common cancer worldwide, the most common
among women, and the most frequent cause of death among women in less developed …

BACKGROUND There is uncertainty about the chemotherapy sensitivity of some oestrogen
receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast …

Background Multi-parameter genomic tests identify patients with early-stage breast cancer
who are likely to derive little benefit from adjuvant chemotherapy. These tests can potentially …

Objective This article provides a systematic and critical review of the evolving methods and
applications of value of information (VOI) in academia and practice and discusses where …

PURPOSE We undertook this study to evaluate the incremental cost per quality-adjusted life-
year (QALY) gained with use of adjuvant trastuzumab as compared with chemotherapy …

Abstract Purpose Neoadjuvant CT-P6, a trastuzumab biosimilar, demonstrated equivalent
efficacy to reference trastuzumab in a phase 3 trial of HER2-positive early-stage breast …

Objectives: Differential pricing, based on countries' purchasing power, is recommended by
the World Health Organization to secure affordable medicines. However, in developing …